1-(3-溴苯基)-1,4-二氢[1,8]二氮杂萘-4-酮-3-甲酰胺 | 1055073-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-(3-溴苯基)-1,4-二氢[1,8]二氮杂萘-4-酮-3-甲酰胺
• 英文名称: 1-(3-Bromophenyl)-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide
• 英文别名: 1-(3-Bromophenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide；1-(3-bromophenyl)-4-oxo-1,8-naphthyridine-3-carboxamide
• CAS: 1055073-66-9
• 化学式: C₁₅H₁₀BrN₃O₂
• 分子量: 344.167
• InChiKey: OTKCGYHRNLGGRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(3-Bromophenyl)-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxylic Acid 、 氨 在 三乙胺 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 为溶剂， 生成 1-(3-溴苯基)-1,4-二氢[1,8]二氮杂萘-4-酮-3-甲酰胺
  参考文献：
  名称：

  Optimization and structure–activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: Identification of MK-0873, a potent and effective PDE4 inhibitor

  摘要：

  A SAR study of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides is described. Optimization of the series was based on in vitro potency against PDE4, inhibition of the LPS-induced production of TNF-alpha in human whole blood and minimizing affinity for the hERG potassium channel. From these studies, compounds 18 and 20 (MK-0873) were identified as optimized PDE4 inhibitors with good overall in vitro and in vivo profiles and selected as development candidates. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.009

文献信息

• 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
  申请人：——

  公开号：US20030096829A1

  公开（公告）日：2003-05-22

  Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.

  由化学式（I）表示的化合物： 1 或其药用可接受的盐，是磷酸二酯酶4抑制剂，用于治疗哮喘和炎症。
• Alkyne-aryl phosphodiesterase-4 inhibitors
  申请人：——

  公开号：US20030114478A1

  公开（公告）日：2003-06-19

  Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.

  由公式(I)表示的化合物： 1 或其药用可接受的盐，是磷酸二酯酶4抑制剂，用于治疗哮喘和炎症。
• Method of preparing inhibitors of phosphodiesterase-4
  申请人：——

  公开号：US20040102472A1

  公开（公告）日：2004-05-27

  In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula V, which are useful in making inhibitors of phosphodiesterase-4: 1 The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula 2

  在一个方面，本发明涉及一种制备Formula V中间体的一锅法，该中间体在制备磷酸二酯酶-4抑制剂时非常有用： 另外，本发明还涉及一种制备磷酸二酯酶抑制剂的方法，包括Formula 2。
• [EN] 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS<br/>[FR] 4-OXO-1-(PHENYL-1,4-DIHYDRO-1,8-NAPTHYRIDINE-3-CARBOXAMIDE, A SUBSTITUTION EN 3, UTILES COMME INHIBITEURS DE PHOSPHODIESTERASE-4
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004048374A1

  公开（公告）日：2004-06-10

  Compounds represented by Formula (I):or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.

  式(I)表示的化合物：或其药学上可接受的盐，是磷酸二酯酶4抑制剂，可用于哮喘和炎症的治疗，并可用于认知能力的增强。
• 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors
  申请人：Dube Daniel

  公开号：US20050107402A1

  公开（公告）日：2005-05-19

  Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.

  公式（I）所代表的化合物或其药学上可接受的盐，是磷酸二酯酶4抑制剂，可用于治疗哮喘和炎症，并有助于增强认知能力。